# Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study

> **NCT07306663** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 242 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** Sintilimab
- **DRUG:** 3-Weekly Paclitaxel plus Carboplatin (TC) Chemotherapy
- **DRUG:** Weekly TC Chemotherapy
- **DRUG:** Four-Weekly TC Consolidation Chemotherapy
- **RADIATION:** Definitive Radiotherapy

## Key facts

- **NCT ID:** NCT07306663
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 242 (ESTIMATED)
- **Last updated:** 2025-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07306663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07306663, "Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07306663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*